导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.56% | 3761/4751 |
| 近一周 | -2.81% | 4266/5440 |
| 近一月 | -1.52% | 1176/5397 |
| 近一季 | -2.37% | 1363/5207 |
| 近半年 | -12.75% | 3800/4896 |
| 近一年 | -16.19% | 3800/4379 |
| 近两年 | 2.46% | 2853/2947 |
| 近三年 | -7.47% | 2000/2246 |
| 成立以来 | -58.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.53% 1840/4961 |
-12.95% 4440/5312 |
- - |
- - |
| 2025 | -6.68% 3379/4813 |
-6.95% 3414/3635 |
2.49% 1539/4076 |
2.47% 3791/4524 |
-4.52% 3459/4813 |
| 2024 | 19.00% 565/3463 |
7.71% 229/2808 |
0.39% 622/3014 |
8.60% 2737/3129 |
1.33% 1084/3463 |
| 2023 | 0.97% 379/2656 |
10.71% 362/2280 |
4.62% 79/2385 |
-5.88% 1389/2515 |
-7.37% 2130/2655 |
| 2022 | -7.22% 138/2207 |
-5.30% 185/1919 |
- 1586/2016 |
-7.63% 137/2113 |
6.06% 393/2208 |
| 2021 | 7.52% 494/1822 |
2.55% 216/1255 |
-2.96% 1233/1330 |
4.15% 378/1466 |
3.75% 395/1822 |
| 2020 | 2.71% 916/1250 |
-3.52% 300/1022 |
-0.63% 1015/1060 |
6.35% 846/1152 |
0.73% 1046/1180 |
| 2019 | 2.32% 807/1092 |
14.99% 688/748 |
-10.83% 745/797 |
-5.42% 792/844 |
5.51% 706/912 |
| 2018 | -26.74% 395/834 |
- - |
- - |
- - |
-5.59% 38/691 |
| 2017 | -7.56% 522/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.47% 376/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 鹏华中证高铁产业指数(LOF)A VS. 长安沪深300非周期A(740101) |